By:
On:

Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen. Conclusion: Adjuvant radiotherapy achieved good local control and showed an acceptable
toxicity profile in patients with high-risk thymomaRead More →

By:
On:

A Multidisciplinary Approach to Therapy for Unresectable Malignant Thymoma
Background: The therapeutic outcome for unresectable, locally advanced, malignant thymoma has been poor.
Objective: To improve tumor resectability and patient survival rates by studying a multimodal approach to therapy for unresectable malignant thymoma.Read More →

By:
On:

Carcinoma of Unknown Primary Site: Sequential Treatment with Paclitaxel/Carboplatin/Etoposide and Gemcitabine/Irinotecan: A Minnie Pearl Cancer Research Network Phase II Trial

Purpose. To evaluate the efficacy and toxicity of the
sequential administration of paclitaxel (Taxol®; BristolMyers Squibb; Princeton, NJ), carboplatin (Paraplatin®;
Bristol-Myers Squibb), and oral etoposide (VePesid®;
Bristol-Myers Squibb) followed by gemcitabine (Gemzar®;
Eli Lilly; Indianapolis, IN) and irinotecan (Campostar®;
Pfizer Pharmaceuticals; New York, NY) in the first-line
treatment of patients with carcinoma of unknown
primary site.
Read More →

By:
On:

Shortly before his death in 1995, Kenneth B. Schwartz, a cancer patient at Massachusetts General Hospital (MGH), founded The Kenneth B. Schwartz Center at MGH. The Schwartz Center is a nonprofit organization dedicated to supporting and advancing compassionate health care delivery, which provides hope to the patient and support to caregivers and encourages the healing process. The center sponsors the Schwartz Center Rounds, a monthly multidisciplinary forum where caregivers reflect on important psychoso- cial issues faced by patients, their families, and their caregivers, and gain insight and support from fellow staff members.

Read More →

By:
On:

Two Cases of Thymic Carcinoma Initially Presenting as Bone Metastasis: A Clinical Report and the Usefulness of CD5 Immunohistochemistry for Assessing Bone LesionsRead More →

By:
On:

Clinical and immunohistochemical study of eight cases with thymic carcinoma
Conclusions: In this small series, it is suggested that a complete resection suggests a favorable
result. Immunohistochemical results reveal that the expression of these proteins might indicate the
aggressiveness of thymic carcinoma.
Background
Thymic carcinoma is a rare type of malignant tumor [1,2].
It is more invasive and with a poorer prognosis than Thymoma.Read More →

By:
On:

Methods: We analyzed seven cases of primary thymic carcinoma, treated with various chemotherapy regimens in our hospital from 1990 to 1999, and carried out a literature review of case reports of thymic carcinoma successfully treated with chemotherapy.
Results: All four cases who received modified ADOC therapy obtained partial responses. Other chemotherapeutic regimens (CHOP-E, PVB) were not effective.
Conclusion: Based on the results of this study and the literature review, we feel that a positive response is obtainable with chemotherapy for thymic carcinoma. Modified ADOC therapy showed consistent efficacy in thymic carcinoma in this study.Read More →